Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01734928
Title Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene Corporation
Indications

multiple myeloma

Therapies

Pomalidomide

Bortezomib + Dexamethasone

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.